|ECR 2018 / C-3001|
|Transarterial Chemo-embolisation with degradable starch microspheres(DSM-TACE) in intermediate/advanced HCC patients dismissing or inelegible for Sorafenib|
Aims and objectives
According to BCLC staging system, HCC patients with well preserved liver function (Child Pugh A-B), portal vein tumor thrombosis or extrahepatic spread are classified as “advanced” or stage C and they present dismal prognosis. In these kind of patients and in those tumors progressing upon loco-regional therapies, the treatment of choice is represented by Sorafenib, an oral multikinase inihibitor that significant prolongs time to progression but without significant differences in time to symptomatic progression. In particular, about 80% of patients present adverse events (hand-foot syndrome, gastrointestinal symptoms) leading to permanent discontinuation in 11% of cases. In patients ineligible to or dismissing Sorafenib there is no available second-line therapy.
Based on this background, the aim of our study is to evaluate safety, feasibility and effectiveness of transarterial chemoembolisation with degradable-starch-microspheres (DSM-TACE), in the treatment of patients with advanced HCC dismissing or ineligible for multikinase-inhibitor chemotherapy administration (Sorafenib) due to unbearable side effects or clinical contraindications.
DSM-TACE consists in degradable particles loaded with doxorubicin that allows the temporary occlusion of the smaller arterial vessels, improving the therapeutic effect (by reducing the immediate wash-out of the cytostatic agent) and decreasing the risk of systemic toxicity and post-embolic syndrome.
Thematically related posters
ECR 2018 / C-3043
Imaging features of hepatic malignancies during and after interventional radiological procedures: a practical guide for radiologists
ECR 2018 / C-1366
Transluminal biliary forceps biopsy: long term results from a single center experience